Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial

Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial

Background Immunotherapy is becoming a standard of care for non-metastatic muscle-invasive bladder cancer (MIBC). The optimal chemotherapy partner for chemo-immunotherapy combinations remains unknown. We evaluated the efficacy and safety of neoadjuvant avelumab-based regimens in patients with MIBC.M...

Full description

Saved in:
Bibliographic Details
Main Authors: Emmanuel Seront, Ahmad Awada, Nieves Martinez Chanza, Philippe Barthélémy, Lieveke Ameye, Françoise Rothé, Aurélien Carnot, Nuria Kotecki, Sandrine Rorive, Thibault Tricard, Jérémy Blanc, Vinciane Casert, Brieuc Sautois, Jan Van den Brande, Vincent Vanhaudenarde, Lionel Staudacher, Veronique Debien, Jean-Christophe Fantoni, Thierry Roumeguère
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/5/e012045.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/5/e012045.full

Similar Items